Compare Nuvalent Inc (NUVL) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Teradyne, Inc. — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Teradyne, Inc. trades at $372.1 (market cap $52.25B). The key difference: Teradyne, Inc. is far larger — about 5.3× Nuvalent Inc's market cap, and Teradyne, Inc. pays a 0.16% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | TER | |
|---|---|---|
Market Cap | $9.81B | $52.25B |
Sector | Technology | Technology |
52-Week High | $123.96 | $483.84 |
52-Week Low | $72.16 | $90.15 |
Enterprise Value | $8.52B | $52.08B |
Dividend Yield | — | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Teradyne (TER) trades at $374.15, up 16.07% in 24 hours, with strong quarterly earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but maintains solid fundamentals with 22.55% net income margin and 28.75% ROE. Recent institutional activity includes Amova Asset Management reducing its position by 49.5% in Q1 2026 while maintaining bullish analyst consensus.
TER presents compelling growth potential from AI infrastructure expansion but faces valuation concerns with a 61.92 P/E ratio. The upcoming Q2 2026 earnings report on July 28, 2026, will be crucial for validating the AI-driven growth narrative. Risks include competitive pressures and market volatility, though analyst consensus targets $459.60 suggest 23% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
